Dr Reddy's rolls out new generic Ozempic brands
Hyderabad: Dr Reddy's Laboratories has introduced two new generic brands, Obeda Pro and Obeda Plus, to expand its range of Ozempic alternatives, according to product images and marketing materials obtained by Reuters. This move comes after a supply disruption caused a halt in sales of their original Obeda injectable in India's rapidly growing semaglutide market.
Obeda Pro and Obeda Plus are manufactured by different companies than the original Obeda, which faced an impurity issue in its active ingredient in July. The company is likely to discontinue Obeda production and focus on the new brands, as distributors have confirmed. Dr Reddy's claims that the development and launch planning for Obeda Pro and Obeda Plus were underway before the July supply issues.
The presence of multiple semaglutide brands and manufacturing arrangements is part of their portfolio strategy, not a replacement for any product.
Written by urgent.news from The Economic Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
